Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Silo Pharma (SILO) Shares Outstanding (Weighted Average) (2019 - 2025)

Silo Pharma (SILO) has disclosed Shares Outstanding (Weighted Average) for 7 consecutive years, with $8.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 127.76% to $8.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.4 million through Dec 2025, up 127.76% year-over-year, with the annual reading at $8.4 million for FY2025, 127.76% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $8.4 million in Q4 2025 for Silo Pharma, up from $34037.0 in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $91.0 million in Q2 2021 to a low of $34037.0 in Q3 2024.
  • Historically, Shares Outstanding (Weighted Average) has averaged $11.3 million across 5 years, with a median of $2.9 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): skyrocketed 260.71% in 2021 and later crashed 98.91% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $1.9 million in 2021, then grew by 20.39% to $2.3 million in 2022, then surged by 34.83% to $3.1 million in 2023, then increased by 19.5% to $3.7 million in 2024, then skyrocketed by 127.76% to $8.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for SILO at $8.4 million in Q4 2025, $34037.0 in Q3 2025, and $6.3 million in Q2 2025.